Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryViva Health Qalsody (tofersen) Coverage & Prior Au…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0704

    Qalsody (tofersen) (Intrathecal) — Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0704 alerts

    Get alerted when Policy IC-0704 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing, eligibility, renewal, billing codes, and documentation requirements for intrathecal Qalsody (tofersen) in members with SOD1-mutant ALS under Viva Health.

    Policy Summary
    PayerViva Health
    PolicyQalsody (tofersen) (Intrathecal) — Coverage Criteria
    Policy CodePolicy IC-0704
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial PA valid 6 months; renewals every 12 months) and document age, baseline NfL, SOD1 mutation, %SVC, and ALSFRS-R scores.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum member age for therapy
    6 moinitial prior authorization duration
    q28dmaintenance dosing interval after loading
    J1304HCPCS billing code and unit definition

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    SOD1 required
    genetic requirement for coverage

    Coverage Criteria for Qalsody (tofersen)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial eligibility: Member is at least 18 years of age; AND member has a baseline plasma neurofilament light chain (NfL) measurement; AND member has a diagnosis of clinically definite or probable ALS based on El Escorial revised criteria, Gold Coast criteria, or Awaji criteria; AND presence of a pathogenic SOD1 gene mutation; AND slow vital capacity (%SVC) ≥ 65%; AND baseline documentation of retained functionality for most activities of daily living (i.e., score of 2 or better on each individual ALSFRS-R item).age >= 18; %SVC >= 65%; ALSFRS-R item scores >= 2

    See ALSFRS-R definition and scoring in source (chunk 5).

    Continuation/Renewal Therapy

    Renewal may be authorized when ALL of the following are met:

    Renewal eligibility: Member continues to meet the indication-specific criteria from initial approval; AND absence of unacceptable toxicity from the drug (examples include serious myelitis/radiculitis, papilledema/elevated intracranial pressure, aseptic meningitis); AND member has improvement in plasma NfL levels compared to baseline; AND member demonstrates disease stability or mild progression (no rapid progression) on the ALSFRS-R compared to pretreatment baseline; AND member does not have a cumulative ALSFRS-R score ≤ 3.ALSFRS-R cumulative score > 3

    Unacceptable toxicity examples are illustrative, not exhaustive.

    Therapy is considered inappropriate when the member experiences unacceptable toxicity attributable to intrathecal tofersen. The policy lists illustrative examples of such toxicity including serious myelitis or radiculitis, papilledema or elevated intracranial pressure, and aseptic meningitis. These examples are intended to be illustrative, not exhaustive, and the presence of such adverse events can preclude renewal of authorization.

    Members without a documented pathogenic SOD1 mutation, or who do not meet the required ALS diagnostic or baseline functional and respiratory thresholds, are not eligible for coverage. Specifically, the policy requires a diagnosis of clinically definite or probable ALS using El Escorial revised, Gold Coast, or Awaji criteria; a baseline %SVC ≥ 65%; and baseline documentation of retained function with a score of 2 or better on each individual ALSFRS‑R item.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J1304Injection, tofersen, 1 mg; 1 billable unit = 1 mg
    NDCNDC
    64406-0109-xx100 mg/15 mL solution in a single-dose glass vial (preservative free)
    Covered Diagnosis CodesICD-10Covered
    G12.21Amyotrophic lateral sclerosis
    inv-08: Slow vital capacity
    Threshold%SVC ≥ 65%
    MeasurementSlow vital capacity reported as percent predicted (%SVC)
    Requirement contextRequired at baseline for initial coverage eligibility

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; duration and billing code

    Prior authorization is required for Qalsody (tofersen). The initial prior authorization validity will be provided for 6 months (180 days); renewals may be authorized every 12 months (365 days) thereafter. Use HCPCS code J1304 (Injection, tofersen, 1 mg; 1 billable unit = 1 mg) for billing.

    • Initial PA: 6 months (180 days).
    • Renewal interval: every 12 months (365 days).
    • Billing code: J1304 (1 mg/unit).
    Note

    NQTL justification: cost-driven PA

    Prior authorization is applied in part due to the cost of the drug, as noted in the NQTL (Non‑Quantitative Treatment Limitations) checklist where 'Cost of drug' was identified as a factor prompting consideration for PA.

    • NQTL checklist identifies 'Cost of drug' as a reason to consider prior authorization.

    Background

    Qalsody (tofersen) is an intrathecal antisense oligonucleotide indicated for ALS due to pathogenic SOD1 mutations. This policy establishes coverage with criteria that define required diagnostic documentation (accepted ALS diagnostic criteria), baseline respiratory and functional thresholds (%SVC ≥ 65% and minimum ALSFRS‑R item scores of 2), and monitoring requirements such as baseline and on‑treatment plasma neurofilament light chain (NfL). Renewal decisions require continued meeting of initial criteria, absence of unacceptable toxicity, improvement in plasma NfL from baseline, and disease stability or slowed decline on ALSFRS‑R.

    Definitions and Clinical Measures

    inv-14: ALS Functional Rating Scale - Revised (ALSFRS-R)
    DefinitionALSFRS‑R is a 12-item questionnaire assessing functional disease progression across four domains: bulbar, fine motor, gross motor, and respiratory.
    ScoringEach item scored 0–4 (0 = loss/significant impairment; 4 = normal); cumulative possible score = 48.
    Use in policyBaseline documentation requires a score of 2 or better on each individual ALSFRS‑R item (corresponds to minimum total of 24).
    inv-15: SOD1 mutation
    DefinitionPresence of a mutation in the superoxide dismutase 1 (SOD1) gene.
    Role in coverageRequired genetic finding for initial eligibility under the policy (must be documented).
    Policy Summary
    PayerViva Health
    PolicyQalsody (tofersen) (Intrathecal) — Coverage Criteria
    Policy CodePolicy IC-0704
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial PA valid 6 months; renewals every 12 months) and document age, baseline NfL, SOD1 mutation, %SVC, and ALSFRS-R scores.
    SourceLink
    On This Page
    Coverage Criteria for Qalsody (tofersen)Billing and CodingProvider Actions, Prior Authorization, and DocumentationBackgroundDefinitions and Clinical Measures
    Documentation Required

    Required documentation to support prior authorization

    Providers must submit specific clinical and billing documentation with PA requests to establish eligibility and allow review.

    • Member age: documentation that member is at least 18 years of age.
    • Baseline plasma neurofilament light chain (NfL) measurement.
    • Diagnosis documentation: clinically definite or probable ALS based on El Escorial revised, Gold Coast, or Awaji criteria.
    • Genetic confirmation of a pathogenic SOD1 gene mutation.
    • Baseline respiratory function: slow vital capacity (%SVC) ≥ 65%.
    • Baseline functional status: ALSFRS‑R item scores documented with each individual item ≥ 2.
    • Dosing plan consistent with intrathecal administration.
    • Billing units: use HCPCS J1304 (1 mg per billable unit) for claims.
    Denial Risk

    Renewal denial triggers

    Renewal requests may be denied if evidence shows unacceptable toxicity, lack of biomarker improvement, or rapid clinical decline while on therapy.

    • Unacceptable toxicity examples include serious myelitis/radiculitis, papilledema/elevated intracranial pressure, aseptic meningitis.
    • No improvement in plasma NfL levels compared to baseline may lead to denial.
    • Rapid disease progression on therapy or a cumulative ALSFRS‑R score ≤ 3 may result in denial of renewal.
    Diagnostic contextListed alongside clinical ALS diagnostic criteria and baseline functional/respiratory thresholds as an eligibility requirement.